

## 🤲 Pharmaids Pharmaceuticals Limited

PPL/BSE/1Q/0011/2019-20

To, The Corporate Relation Department, The Stock Exchange, Mumbai, 1 st Floor, Rotunda

Building,

Dalai Street, MUMBAI-400001

BSE Security Code:524572

Sub: Outcome of Board Meeting held on August 13th, 2019.

August 13th, 2019

We wish to inform you that the Board Directors of the Company, at their just concluded meeting and Approved the Unaudited Financial Results of the Company for the Quarter ended June 30, 2019.

We are here with enclosing the Unaudited financial results for Quarter ended June 30, 2019 along with the Limited Review Report issued by the statutory auditors of the Company.

Further, in compliance with Regulation 33 of Listing Regulations and SEBI Circular No. CFD/DlL3/CIR/2017/21 dated March 10, 2017, the Board hereby declares/certifies that the statutory auditors of the Company have submitted their Limited Review Report for the Quarter ended June 30,2019 results of the Company for the FY 2019-20 with an unmodified and unqualified opinion.

The meeting commenced at 11.00 A.M. and concluded at 2.00 P.M.

This for your information and dissemination to the public.

For PHARMAIDS PHARMACEUTICALS LIMITED

**Authorised Signato** 

CIN No. L52520TG1989PLC009679





## 🦀 Pharmaids Pharmaceuticals Limited

Particulars	Particulars	QUARTER ENDED			YEAR ENDED
National		- i			March 2019
Income   Revenue from Operations   0.00		********			Audited
Revenue from Operations	Income	Onadanca	Audiceu	Onadarted	Addited
Other Income		0.00	0.00	0.00	48.10
Total Income   0.00   0.24   0.01					0.52
Expenses	The state of the s				48.62
Cost of Material Consumed   0.00	- Endertin				
Purchase of Stock in Trade Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,	244.00140.00	0.00	0.00	0.00	0.00
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade  Employee benefit expenses  O.96  Depreciation and amortisation expense  O.00  O	Purchase of Stock in Trade				35.62
and Stock in Trade			0.00	0.00	55.02
Employee benefit expenses   0.96   0.92   0.86		0.00	0.00	0.00	0.00
Finance Cost					2.83
Depreciation and amortisation expense   0.04   0.07   0.02					0.05
Total expenses   5.78   4.86   2.72	Depreciation and amortisation expense				0.14
Total expenses   6.87   5.87   3.60		5.78	4.86		24.75
Profit/ (loss) before exceptional items and tax  (6.87) (5.63) (3.59)  Exceptional items  (0.00 0.00 0.00  Profit/ (loss) before tax  (6.87) (5.63) (3.59)  Tax expenses  (0.00 0.00 0.00  Profit/ (loss) for the period from continuing operations  (0.00 0.00 0.00  Profit/ (loss) from discontinued operations  (0.00 0.00 0.00  Profit/ (loss) from discontinued operations  (0.00 0.00 0.00  Profit/ (loss) from discounting operations  (0.00 0.00 0.00  Profit/ (loss) from discounting operations (after tax)  (0.00 0.00 0.00  Profit/ (loss) for the period  (6.87) (5.63) (3.59)  Other comprehensive income  (0.00 0.00 0.00  Profit/ loss + other comprehensive income)  (0.00 0.00 0.00  Profit/ loss + other comprehensive income)  (0.00 0.00 0.00  Diarnings per equity share (for continuing operations)  (0.20) (0.17) (0.11)  Parnings per equity share (for discontinued operations)  (0.20) 0.00 0.00  Diluted  (0.20) 0.00 0.00  O.00  O.00					63.39
Exceptional items		(6.87)			(14.77)
Tax expenses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0					0.00
Tax expenses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	Profit/ (loss) before tax	(6.87)	(5.63)	(3.59)	(14.77)
0.00	Tax expenses				0.00
0.00   0.00	Profit / (loss) for the period from continuing enerations				
Profit/ (loss) from discontinued operations	ronty (loss) for the period from continuing operations	0.00	0.00	0.00	0.00
Profit/ (loss) from discounting operations (after tax)  0.00	Profit/ (loss) from discontinued operations	0.00			0.00
0.00   0.00	ax expense of discontinued operations	0.00	0.00	0.00	(3.70)
0.00   0.00	Profit / (loss) from discounting operations (after tay)				
Other comprehensive income	Tony (1035) from discounting operations (after tax)	0.00	0.00	0.00	0.00
Total comprehensive income for the period   0.00		(6.87)	(5.63)	(3.59)	(18.47)
(Profit/ loss + other comprehensive income)  Garnings per equity share (for continuing operations)  Di Basic  (0.20)  (0.17) (0.11)  Garnings per equity share (for discontinued operations)  Di Basic  (0.20)  (0.17) (0.11)  Garnings per equity share (for discontinued operations)  Di Basic  (0.20)  O.00  O.	Other comprehensive income	0.00	0.00	0.00	0.00
Earnings per equity share (for continuing operations)  (a) Basic (0.20) (0.17) (0.11)  (b) Diluted (0.20) (0.17) (0.11)  (arnings per equity share (for discontinued operations)  (b) Basic (0.00) (0.00) (0.00)  (c) Diluted (0.00) (0.00) (0.00)  (d) Diluted (0.20) (0.17) (0.11)	otal comprehensive income for the period	0.00	0.00	0.00	0.00
Basic	(Profit/ loss + other comprehensive income)	0.00	0.00	0.00	0.00
Basic	-				
o) Diluted (0.20) (0.17) (0.11)  Farnings per equity share (for discontinued operations)  1) Basic 0.00 0.00 0.00  2) Diluted 0.00 0.00 0.00  Farnings per equity share (for discontinued & continuing perations)	arnings per equity share (for continuing operations)				
arnings per equity share (for discontinued operations) ) Basic 0.00 0.00 0.00 ) Diluted 0.00 0.00 0.00 arnings per equity share (for discontinued & continuing perations)	) Basic	(0.20)	(0.17)	(0.11)	(0.54)
) Basic 0.00 0.00 0.00 0.00 ) Diluted 0.00 0.00 0.00 arnings per equity share (for discontinued & continuing perations)	) Diluted	(0.20)	(0.17)	(0.11)	(0.54)
) Basic 0.00 0.00 0.00 0.00 ) Diluted 0.00 0.00 0.00 arnings per equity share (for discontinued & continuing perations)					
) Diluted 0.00 0.00 0.00 arnings per equity share (for discontinued & continuing perations)					
perations)					0.00
perations)		0.00	0.00	0.00	0.00
) Basic (0.20) (0.17) (0.11) ) Diluted (0.20) (0.17) (0.11)					(0.54)

NOTES: 1. These results were approved at the meeting of the Board of Directors held on August 13,2019. 2. The Company operates in a single segment 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the current period.

Place: Hyderabad Date: 13/08/2019

For Pharmaids Pharmaceuticals Limited Chrus

Ghisulal Jain Managing Director (DIN.No:00404983)

## Chartered Accountants PPKG & Co

JESTO JOSEPH PROTECTION OF THE PROTECTION OF THE

## LIMITED REVIEW REPORT

To
The Board of Directors,
M/s Pharmaids Pharmaceuticals Limited,
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of PHARMAIDS PHARMACEUTICALS LIMITED for the Quarter Ended 30<sup>th</sup> June, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and subject to the non presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & CO Chartered Accountants FRN No. 0096558

GIRDHARI LA

Partner

M, No. 205140

Autociale Office al

AHMEDABAD - ASSAM - BANGALOFE - CHENNAL - DELFIL

GEOVARIATI « JAIPLIR » RISLIKATA « MUMEREI » TRIMINDRUM

Batgach

A Network Approved by ICAI